# US 2010/0305034 A1 · Growth factor isoform

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0305034 A1
- Document ID: US20100305034A1
- Status: Published application
- Kind: A1
- Application number: 12/768,365
- Filed: 2010-04-27
- Published: 2010-12-02
- Earliest claimed: 2001-08-01
- Assignees: The University of Bristol
- Inventors: DAVID BATES; STEVEN HARPER
- Web page: https://patentgrep.com/patent/US20100305034A1

## CPC

- C07K 14/475: Growth factors; Growth regulators
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2310/14: interfering nucleic acids [NA]
- G01N 2333/475: Assays involving growth factors
- G01N 2333/515: Angiogenesic factors; Angiogenin
- G01N 2333/71: for growth factors; for growth regulators
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

An isolated VEGF polypeptide having anti-angiogenic activity, said polypeptide including the amino acid sequence of SEQ.ID NO.1, or variants thereof.

## Claims

### Claim 1

An isolated VEGF polypeptide comprising an amino acid sequence at least 80% identical to the C-terminal 165 amino acid sequence from SEQ ID NO:17, wherein the polypeptide inhibits pro-angiogenic VEGF receptors activity.

### Claim at position 2

2-5. (canceled)

### Claim 6 (depends on 1)

An isolated nucleotide sequence capable of encoding a VEGF polypeptide according to claim 1.

### Claim at position 4

7-8. (canceled)

### Claim 9

An isolated nucleotide sequence comprising a nucleotide sequence that hybridises under stringent conditions to the nucleotide sequence of SEQ.ID.NO:2, or variants thereof.

### Claim 10 (depends on 6)

An isolated nucleotide sequence according to claim 6 wherein the nucleotide sequence is selected from the group consisting of unprocessed RNA, ribozyme RNA, hairpin siRNA, siRNA, mRNA, cDNA, genomic DNA, B-DNA, E-DNA and Z-DNA.

### Claim at position 7

11-18. (canceled)

### Claim 19 (depends on 1)

A method for treating or preventing angiogenesis in a mammalian patient comprising supplying to the patient a polypeptide comprising the sequence of a VEGF polypeptide according to claim 1.

### Claim 20 (depends on 6)

A method for treating or preventing angiogenesis in a mammalian patient comprising supplying to the patient a polynucleotide comprising a nucleotide sequence according to claim 6.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A method for preventing or reducing VEGF-mediated cell proliferation in a mammalian patient comprising supplying to the patient a polypeptide comprising the sequence of an isolated VEGF polypeptide according to claim 1.

### Claim 23 (depends on 6)

A method for preventing or reducing VEGF-mediated cell proliferation in a mammalian patient comprising supplying to the patient a polynucleotide comprising the sequence of an isolated nucleotide according to claim 6.

### Claim 24

(canceled)

### Claim 25 (depends on 6)

A pharmaceutical composition for the prevention or reduction of VEGF-mediated cell proliferation comprising the nucleotide sequence to claim 6, and a pharmaceutically acceptable diluent.

### Claim at position 15

26-32. (canceled)

### Claim 33 (depends on 1)

A pharmaceutical composition comprising a VEGF polypeptide according to claim 1 and a pharmaceutically acceptable diluent.

### Claim 34 (depends on 6)

A pharmaceutical composition comprising a nucleotide sequence according to claim 6 and a pharmaceutically acceptable diluent.

### Claim 35 (depends on 6)

An expression vector comprising a nucleotide sequence according claim 6.

### Claim 36 (depends on 34)

A host cell comprising an expression vector according to claim 34.

### Claim 37

(canceled)

### Claim 38 (depends on 1)

An antibody raised against a polypeptide comprising the sequence of a VEGF polypeptide according to claim 1.

### Claim 39 (depends on 6)

An antibody produced against a polynucleotide comprising a nucleotide sequence according to claim 6.

### Claim at position 23

40-41. (canceled)

### Claim 42 (depends on 1)

A method of screening compounds to identify an agonist of the anti-angiogenic activity of a polypeptide according to claim 1 wherein said polypeptide and a labelled ligand of said polypeptide are incubated in the presence and absence of a candidate compound, wherein increased anti-angiogenic activity of said peptide in the presence of said candidate compound when compared to the anti-angiogenic activity in the absence of said compound indicates that the candidate compound is an agonist.

### Claim 43 (depends on 42)

A method according to claim 42, comprising the steps of:
a) incubating the polypeptide and the labeled ligand in the presence and absence of a candidate compound;
b) comparing the anti-angiogenic activity of the peptide incubated in the presence of the candidate compound with the anti-angiogenic activity of the peptide incubated in the absence of the candidate compound;
wherein increased anti-angiogenic activity of the peptide incubated in the presence of the candidate compound compared with the anti-angiogenic activity of the peptide incubated in the absence of the candidate compound indicates that the candidate compound is an agonist.

### Claim 44

(canceled)

### Claim 45 (depends on 1)

A method of screening compounds to identify an antagonist of the anti-angiogenic activity of a polypeptide according to claim 1 wherein said polypeptide and a labelled ligand of said polypeptide are incubated in the presence and absence of a candidate compound, wherein decreased anti-angiogenic activity of said peptide in the presence of said candidate compound when compared to the anti-angiogenic activity in the absence of said compound indicates that the candidate compound is an antagonist.

### Claim 46 (depends on 45)

A method according to claim 45, comprising the steps of:
a) incubating the polypeptide and the labeled ligand in the presence and absence of a candidate compound;
b) comparing the anti-angiogenic activity of the peptide incubated in the presence of the candidate compound with the anti-angiogenic activity of the peptide incubated in the absence of the candidate compound;
wherein increased anti-angiogenic activity of the peptide incubated in the presence of the candidate compound compared with the anti-angiogenic activity of the peptide incubated in the absence of the candidate compound indicates that the candidate compound is an antagonist.

### Claim at position 29

47-59. (canceled)

### Claim 60

An assay for the specific detection of VEGF165b in a sample comprising carrying out a polymerase chain reaction on at least a portion of the sample, using an annealing temperature of at least 59° C. and the following primer sequences:
exon 4 (forward primer):
GAGATGAGCTTCCTACAGCAC
9H (reverse primer):
TTAAGCTTTCAGTCTTTCCTGGTGAGAGATCTGCA
or variants thereof, wherein the variants retain the same annealing properties with respect to the VEG165 nucleotide sequence as the above primers.

### Claim at position 31

61-62. (canceled)
